Oral Mucositis Market, Growth and Trends By Cause (Oral Mucositis Caused by Chemotherapy, Oral Mucositis Caused by Radiotherapy, Oral Mucositis Caused by Hematopoietic Stem Cell Transplantation, and Others), End-User (Hospitals, Dental Clinics, Oncology Hospitals, and Research Institutes), and Region (Americas, Europe, Asia-Pacific, and Middle East & Africa)—Global Forecast till 2025

Market Scenario
The global Oral Mucositis Market size is expected to register 7.1% CAGR during the forecast period of 2019 to 2025, with a market value of USD 2,247 million in 2018. Oral mucositis is an acute inflammation or ulceration of the oral or oropharyngeal mucosal membranes. It can cause pain/discomfort, interfere with swallowing, eating, and speech, and may lead to infection. The global oral mucositis market is driven by factors such as rising incidences of cancer globally and increasing oral mucositis drug development. For instance, according to the National Center for Biotechnology Information, oral mucositis occurs in up to 40% of cancer patients that receive chemotherapy and approaches 100% in the treatment of head and neck cancers. Additionally, according to National Cancer Institute, an estimated 1,735,350 new cases of cancer were diagnosed in the US in 2018. Furthermore, according to the US Department of Health and Human Services, the prevalence of cancer in the US is 439.2 per 100,000 men and women. Moreover, according to WHO, there are 3.7 million cases of cancer in Europe every year. On the other hand, most of the drugs are not to be ingested, which restricts their usage for oral mucositis is projected to hamper the growth of the market during the assessment period. Moreover, major companies in the market are involved in strategic acquisitions, collaborations, and mergers, and receive new patents to sustain their position in the market. For instance, in February 2019, Innovation Pharmaceuticals receives new patent for compounds for use in treatment of oral mucositis. The patent covers methods for treating and/or preventing mucositis with one or more compounds, or pharmaceutically acceptable salts.

Oral Mucositis Market Segmentation
The global oral mucositis market has been segmented based on cause, end user, and region. The market, based on cause, has been bifurcated into oral mucositis caused by chemotherapy, oral mucositis caused by radiotherapy, and oral mucositis caused by hematopoietic stem cell transplantation

The global market, based on end user, has been segmented into hospitals, dental clinics, oncology hospitals, and research institutes. Based on cause, the oral mucositis caused by chemotherapy segment is expected to hold a major share in the market as chemotherapy is widely used as a treatment method for cancer. For example, according to the US Department of Health & Human Services, every year, about 650,000 cancer patients receive chemotherapy in an outpatient oncology clinic in the US. Based on end user, the hospitals segment is expected to hold a major share in the market due to its close association with cancer availability of all possible treatment options.

The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The oral mucositis market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada. The European oral mucositis market has been sub-divided into Western Europe and Eastern Europe.
Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The oral mucositis market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The oral mucositis market in the Middle East & Africa has been divided into the Middle East and Africa.

Global Oral Mucositis Market, by Cause

- Oral Mucositis Caused by Chemotherapy
- Oral Mucositis Caused by Radiotherapy
- Oral Mucositis Caused by Hematopoietic Stem Cell Transplantation

Global Oral Mucositis Market, by End User

- Hospitals
- Dental Clinics
- Oncology Hospitals
- Research Institutes

Key Players

The key players operating in the global oral mucositis market are Izun Pharmaceuticals Corporation, Shoreline Pharmaceuticals, Inc, AMAG Pharmaceutical Inc, Innovation Pharmaceuticals, The Himalaya Drug Company, Access pharmaceuticals, EKR therapeutics Inc, EUSA Pharma Inc, Swedish Orphan Biovitrum AB (publ), Soligenix, and Daewoong Co. Ltd.

Regional Market Summary:

Global Oral Mucositis Market Share by Region, 2018 (%)

Source: World Health Organization (WHO)

The market in the Americas is expected to dominate the oral mucositis market due to the increasing incidences of head and neck cancers. For example, according to the American Society of Clinical Oncology (ASCO), head and neck cancer account for about 4% of all cancers in the US. In 2019, an estimated 65,410 people will develop head and neck cancer. High cases of cancer in the US and Canada is expected to drive the market growth. Furthermore, increasing expenses in research by healthcare bodies engaged in improving oral mucositis treatment are the factors contributing to its largest share is expected to fuel the growth of the market in this region. The market in Europe showed a considerable amount of growth. This can be attributed to the presence of a well-established healthcare system, an increase in cancer diseases, and the involvement of key companies. For instance, in April 2016, EUSA Pharma announces the acquisition of global rights to next-generation oncology supportive care product Arcoral Tab from Arcoral Pharma. The market in Asia-Pacific is projected to have a steady growth rate during the forecast period owing to the increasing prevalence of cancer and increasing government initiatives for healthcare reforms. The market in the Middle East & Africa is projected to account for the least share of the global market due to low per capita disposable income in the region.

Global Oral Mucositis Market, by Region
• Americas
  • North America
    • US
    • Canada
  • Latin America

• Europe
  • Western Europe
    • Germany
    • France
    • Italy
    • Spain
    • UK
    • Rest of Western Europe
  • Eastern Europe

• Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific

• Middle East & Africa
  • Middle East
  • Africa

Intended Audience
• Research and development (R&D) companies
• Medical device companies
• Government research institutes
• Academic institutes and universities
• Venture capitalists

Contents:
Table of Contents:
Chapter 1. Report Prologue
Chapter 2. Market Introduction
  2.1 Definition
  2.2 Scope of the Study
  2.2.1 Research Objective
  2.2.2 Assumptions
  2.2.3 Limitations
Chapter 3. Research Methodology
  3.1 Overview
  3.2 Primary Research
  3.3 Secondary Research
  3.4 Market Size Estimation
Chapter 4. Market Dynamics
  4.1 Drivers
  4.2 Restraints
  4.3 Opportunities
  4.4 Challenges
Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

Chapter 6. Global Oral Mucositis Market, by Cause

6.1 Overview
6.2 Oral Mucositis Caused by Chemotherapy
Market Estimates & Forecast, by Region, 20112–2025
6.3 Oral Mucositis Caused by Radiotherapy
Market Estimates & Forecast, by Region, 20112–2025
6.4 Oral Mucositis Caused by Hematopoietic Stem Cell Transplantation
Market Estimates & Forecast, by Region, 20112–2025
6.5 Others
Market Estimates & Forecast, by Region, 20112–2025

Chapter 7. Global Oral Mucositis Market, by End Use

7.1 Overview
7.2 Hospitals
Market Estimates & Forecast, by Region, 20112–2025
7.2 Dental Clinics
Market Estimates & Forecast, by Region, 20112–2025
7.2 Oncology Hospitals
Market Estimates & Forecast, by Region, 20112–2025
7.2 Research Institutes
Market Estimates & Forecast, by Region, 20112–2025

Chapter 8. Global Oral Mucositis Market, by Region

8.1 Overview
8.2 Americas
8.2.1 North America
8.2.1.1 US
8.2.1.2 Canada
8.2.2 Latin America
8.3 Europe
8.3.1 Western Europe
8.3.1.1 Germany
8.3.1.2 France
8.3.1.3 Italy
8.3.1.4 Spain
8.3.1.5 UK
8.3.1.6 Rest of Western Europe
8.3.2 Eastern Europe
8.4 Asia-Pacific
8.4.1 Japan
8.4.2 China
8.4.3 India
8.4.4 Australia
8.4.5 South Korea
8.4.6 Rest of Asia-Pacific
8.5 Middle East & Africa
8.5.1 Middle East
8.5.2 Africa

Chapter 9. Company Landscape
9.1 Overview
9.2 Competitive Analysis

Chapter 10. Company Profile
10.1 Izun Pharmaceuticals Corporation
10.1.1 Company Overview
10.1.2 Product Type Overview
10.1.3 Financials Overview
10.1.4 Key Developments
10.1.5 SWOT Analysis
10.2 Shoreline Pharmaceuticals, Inc
10.2.1 Company Overview
10.2.2 Product Type Overview
10.2.3 Financial Overview
10.2.4 Key Developments
10.2.5 SWOT Analysis
10.3 AMAG Pharmaceutical Inc
10.3.1 Company Overview
10.3.2 Product Type Overview
10.3.3 Financial Overview
10.3.4 Key Development
10.3.5 SWOT Analysis
10.4 Innovation Pharmaceuticals
10.4.1 Company Overview
10.4.2 Product Type Overview
10.4.3 Financial Overview
10.4.4 Key Development
10.4.5 SWOT Analysis
10.5 The Himalaya Drug Company
10.5.1 Company Overview
10.5.2 Product Type Overview
10.5.3 Financial overview
10.5.4 Key Developments
10.5.5 SWOT Analysis
10.6 Access pharmaceuticals
10.6.1 Company Overview
10.6.2 Product Type Overview
10.6.3 Financial Overview
10.6.4 Key Developments
10.6.5 SWOT Analysis
10.7 EKR therapeutics Inc
10.7.1 Overview
10.7.2 Product Type Overview
10.7.3 Financial Overview
10.7.4 Key Developments
10.7.5 SWOT Analysis
10.8 EUSA Pharma Inc
10.8.1 Overview
10.8.2 Product Type Overview
10.8.3 Financials
10.8.4 Key Developments
10.8.5 SWOT Analysis
10.9 Swedish Orphan Biovitrum AB (publ)
10.9.1 Overview
10.9.2 Product Type Overview
10.9.3 Financials
10.9.4 Key Developments
10.9.5 SWOT Analysis
10.10 Soligenix
10.10.1 Overview
10.10.2 Product Type Overview
10.10.3 Financials
10.10.4 Key Developments
10.10.5 SWOT Analysis
10.11 Daewoong co Ltd
10.11.1 Overview
10.11.2 Product Type Overview
10.11.3 Financials
10.11.4 Key Developments
10.11.5 SWOT Analysis
10.12 Others

Chapter 11 Appendix
11.1 References
11.2 Related Reports

LIST OF TABLES
Table 1 Global Oral Mucositis Market Synopsis, 20102–2025
Table 2 Global Oral Mucositis Market Estimates and Forecast, 20102–2025 (USD Million)
Table 3 Global Oral Mucositis Market, by Cause, 20102–2025 (USD Million)
Table 4 Global Oral Mucositis Market, by End Use, 20102–2025 (USD Million)
Table 5 Global Oral Mucositis Market, by Region, 20102–2025 (USD Million)
Table 6 North America: Oral Mucositis Market, by Cause, 20102–2025 (USD Million)
Table 7 North America: Oral Mucositis Market, by End Use, 20102–2025 (USD Million)
Table 8 US: Oral Mucositis Market, by Cause, 20102–2025 (USD Million)
Table 9 US: Oral Mucositis Market, by End Use, 20102–2025 (USD Million)
Table 10 Canada: Oral Mucositis Market, by Cause, 20102–2025 (USD Million)
Table 11 Canada: Oral Mucositis Market, by End Use, 20102–2025 (USD Million)
Table 12 Latin America: Oral Mucositis Market, by Cause, 20102–2025 (USD Million)
Table 13 Latin America: Oral Mucositis Market, by End Use, 20102–2025 (USD Million)
Table 14 Europe: Oral Mucositis Market, by Cause, 20102–2025 (USD Million)
Table 15 Europe: Oral Mucositis Market, by End Use, 20102–2025 (USD Million)
Table 16 Western Europe: Oral Mucositis Market, by Cause, 20102–2025 (USD Million)
Table 17 Western Europe: Oral Mucositis Market, by End Use, 20102–2025 (USD Million)
Table 18 Eastern Europe: Oral Mucositis Market, by Cause, 20102–2025 (USD Million)
Table 19 Eastern Europe: Oral Mucositis Market, by End Use, 20102–2025 (USD Million)
Table 20 Asia-Pacific: Oral Mucositis Market, by Cause, 20102–2025 (USD Million)
Table 21 Asia-Pacific: Oral Mucositis Market, by End Use, 20102–2025 (USD Million)
Table 22 Middle East & Africa: Oral Mucositis Market, by Cause, 20102–2025 (USD Million)
Table 23 Middle East & Africa: Oral Mucositis Market, by End Use, 20102–2025 (USD Million)

LIST OF FIGURES
Figure 1 Research Process
Figure 2 Market Structure for Global Oral Mucositis Market
Figure 3 Market Dynamics for Global Oral Mucositis Market
Figure 4 Global Oral Mucositis Market Share, by Cause, 2018 (%)
Figure 5 Global Oral Mucositis Market Share, by End Use, 2018 (%)
Figure 6 Global Oral Mucositis Market Share, by Region, 2018 (%)
Figure 7 North America: Oral Mucositis Market Share, by Country, 2018 (%)
Figure 8 Europe: Oral Mucositis Market Share, by Region, 2018 (%)
Figure 9 Western Europe: Oral Mucositis Market Share, by Country, 2018 (%)
Figure 10 Asia-Pacific: Oral Mucositis Market Share, by Country, 2018 (%)
Figure 11 Middle East & Africa: Oral Mucositis Market Share, by Country, 2018 (%)
Figure 12 Global Oral Mucositis Market: Company Share Analysis, 2018 (%)
Figure 13 Izun Pharmaceuticals Corporation: Key Financials
Figure 14 Izun Pharmaceuticals Corporation: Segmental Revenue
Figure 15 Izun Pharmaceuticals Corporation: Geographic Revenue
Figure 16 Shoreline Pharmaceuticals, Inc: Key Financials
Figure 17 Shoreline Pharmaceuticals, Inc: Segmental Revenue
Figure 18 Shoreline Pharmaceuticals, Inc: Geographic Revenue
Figure 19 AMAG Pharmaceutical Inc: Key Financials
Figure 20 AMAG Pharmaceutical Inc: Segmental Revenue
Figure 21 AMAG Pharmaceutical Inc: Geographic Revenue
Figure 22 Innovation Pharmaceuticals: Key Financials
Figure 23 Innovation Pharmaceuticals: Segmental Revenue
Figure 24 Innovation Pharmaceuticals: Geographic Revenue
Figure 25 The Himalaya Drug Company: Key Financials
Figure 26 The Himalaya Drug Company: Segmental Revenue
Figure 27 The Himalaya Drug Company: Geographic Revenue
Figure 28 Access pharmaceuticals: Key Financials
Figure 29 Access pharmaceuticals: Segmental Revenue
Figure 30 Access pharmaceuticals: Geographic Revenue
Figure 31 EKR therapeutics Inc: Key Financials
Figure 32 EKR therapeutics Inc: Segmental Revenue
Figure 33 EKR therapeutics Inc: Geographic Revenue
Figure 34 EUSA Pharma Inc: Key Financials
Figure 35 EUSA Pharma Inc: Segmental Revenue
Figure 36 EUSA Pharma Inc: Geographic Revenue
Figure 37 Swedish Orphan Biovitrum AB (publ): Key Financials
Figure 38 Swedish Orphan Biovitrum AB (publ): Segmental Revenue
Figure 39 Swedish Orphan Biovitrum AB (publ): Geographic Revenue
Figure 40 Soligenix: Key Financials
Figure 41 Soligenix: Segmental Revenue
Figure 42 Soligenix: Geographic Revenue
Figure 43 Daewoong co Ltd: Key Financials
Figure 44 Daewoong co Ltd: Segmental Revenue
Figure 45 Daewoong co Ltd: Geographic Revenue